True Wealth Design LLC Invests $43,000 in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

True Wealth Design LLC bought a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) in the third quarter, HoldingsChannel reports. The fund bought 778 shares of the biopharmaceutical company’s stock, valued at approximately $43,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. PDT Partners LLC grew its position in Ultragenyx Pharmaceutical by 26.1% during the third quarter. PDT Partners LLC now owns 66,193 shares of the biopharmaceutical company’s stock valued at $3,677,000 after acquiring an additional 13,718 shares during the period. Captrust Financial Advisors lifted its stake in shares of Ultragenyx Pharmaceutical by 129.3% in the 3rd quarter. Captrust Financial Advisors now owns 11,428 shares of the biopharmaceutical company’s stock valued at $635,000 after purchasing an additional 6,445 shares in the last quarter. Capstone Investment Advisors LLC purchased a new stake in shares of Ultragenyx Pharmaceutical during the 3rd quarter worth about $727,000. Hantz Financial Services Inc. acquired a new stake in Ultragenyx Pharmaceutical during the 3rd quarter worth approximately $194,000. Finally, Alkeon Capital Management LLC raised its holdings in Ultragenyx Pharmaceutical by 34.3% in the third quarter. Alkeon Capital Management LLC now owns 3,011,716 shares of the biopharmaceutical company’s stock valued at $167,301,000 after buying an additional 769,884 shares during the period. Institutional investors and hedge funds own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Price Performance

RARE opened at $47.63 on Monday. Ultragenyx Pharmaceutical Inc. has a 12-month low of $37.02 and a 12-month high of $60.37. The stock has a market capitalization of $4.40 billion, a PE ratio of -7.36 and a beta of 0.58. The firm’s fifty day moving average price is $52.04 and its 200 day moving average price is $48.72.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.45) by $0.05. The business had revenue of $139.49 million for the quarter, compared to analyst estimates of $135.28 million. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. The company’s revenue for the quarter was up 42.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($2.23) EPS. On average, equities research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -6.2 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on RARE. Cantor Fitzgerald restated an “overweight” rating and set a $116.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. TD Cowen upped their target price on Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. HC Wainwright increased their target price on Ultragenyx Pharmaceutical from $82.00 to $95.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. JPMorgan Chase & Co. reduced their price target on Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating on the stock in a research report on Thursday, November 21st. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $77.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $87.46.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In related news, CEO Emil D. Kakkis sold 20,000 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $55.85, for a total transaction of $1,117,000.00. Following the completion of the sale, the chief executive officer now owns 2,223,985 shares of the company’s stock, valued at $124,209,562.25. This represents a 0.89 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Howard Horn sold 7,465 shares of the firm’s stock in a transaction dated Thursday, October 10th. The stock was sold at an average price of $52.76, for a total transaction of $393,853.40. Following the completion of the transaction, the chief financial officer now directly owns 92,301 shares in the company, valued at $4,869,800.76. This represents a 7.48 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 27,556 shares of company stock worth $1,515,967 over the last quarter. 5.80% of the stock is owned by corporate insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.